<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349866</url>
  </required_header>
  <id_info>
    <org_study_id>HRA-G01</org_study_id>
    <nct_id>NCT03349866</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction</brief_title>
  <official_title>A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of patients who receive
      concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2
      negative adenocarcinoma at gastroesophageal junction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The pathological complete response rate(pCR)</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
    <description>The lesion disappeared completely by pathology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
    <description>Baseline to measured stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0-resection rate</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
    <description>There was no residual by the microscope</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival(DFS)</measure>
    <time_frame>3 year</time_frame>
    <description>Baseline to measured date of recurrence or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3years</time_frame>
    <description>Baseline to measured date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 year</time_frame>
    <description>Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.The number of Participants with adverse events will be recorded at each treatment visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>apatinib XELOX and radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apatinib：250mg qd po XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX and radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apatinib</intervention_name>
    <description>apatinib：250mg qd po</description>
    <arm_group_label>apatinib XELOX and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000mg/m2 bid d1-14</description>
    <arm_group_label>apatinib XELOX and radiotherapy</arm_group_label>
    <arm_group_label>XELOX and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m2 Ivgtt d1 q3w</description>
    <arm_group_label>apatinib XELOX and radiotherapy</arm_group_label>
    <arm_group_label>XELOX and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>45Gy/25f （1.8Gy/f/d，5 f/w）</description>
    <arm_group_label>apatinib XELOX and radiotherapy</arm_group_label>
    <arm_group_label>XELOX and radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18 to 70 years old (man or female);

          2. Conﬁrmed to Siewert II , III of locally advanced adenocarcinoma at gastroesophageal
             junction and tumor long diameter ≤8 cm by gastroscopy and CT, The her-2 negative was
             detected by immunohistochemistry;

          3. Patients with Stage for Ⅲ by CT/MRI (According to the eighth edition of AJCC );

          4. Patients with measurable lesions(measuring≥10mm on spiral CT scan, satisfying the
             criteria in RECIST1.1);

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

          6. Major organ function has to meet the following certeria:

             HB≥80g/L; ANC≥1.5×109/L; PLT≥90×109/L; ALT and AST≤2.5×ULN, but&lt;≤5×ULN if the
             transferanse elevation is due to liver metastases； TBIL&lt;1.5×ULN； Serum creatinine
             ≤1.5×ULN;

          7. Life expectancy greater than or equal to 6 months;

          8. Women of childbearing age must have contraceptive measures or have test pregnancy
             (serum or urine) enroll the study before 7 days, and the results must be negative, and
             take the methods of contraception during the test and the last to have drugs after 8
             weeks. Men must be contraception or has sterilization surgery during the test and the
             last to have drugs after 8 weeks;

          9. Participants were willing to join in this study, and written informed consent, good
             adherence, cooperate with the follow-up.

        Exclusion Criteria:

          1. Allergic to apatinib, capecitabine and oxaliplatin;

          2. The cytological examination of the abdominal cavity washing fluid showed that the
             tumor shedding cells were positive;

          3. Have high blood pressure and antihypertensive drug treatment can not control (systolic
             blood pressure &gt; 140 mmHg, diastolic blood pressure &gt; 90 mmHg), Uncontrolled coronary
             heart disease and arrhythmia ,classⅢ-Ⅳcardiac insufficiency;

          4. A variety of factors influencing oral drugs (such as unable to swallow, nausea,
             vomiting, chronic diarrhea and intestinal obstruction, etc);

          5. Patients with tendency of gastrointestinal bleeding, including the following: a local
             active ulcerative lesions, and defecate occult blood (+ +); Has melena and hematemesis
             in two months;

          6. Coagulant function abnormality (INR &gt; 1.5 ULN, APTT &gt; 1.5 ULN), with bleeding
             tendency;

          7. Pregnant or lactating women;

          8. Patients with other malignant tumors within 5 years (except for curable skin basal
             cell carcinoma and cervical carcinoma in situ);

          9. History of psychiatric drugs abuse and can't quit or patients with mental disorders;

         10. Less than 4 weeks from the last clinical trial;

         11. The researchers think inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qun Zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University Fourth Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University Fourth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qun Zhao</last_name>
    <phone>13930162111</phone>
    <email>Zhaoqun516@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>ShiJiaZhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qun Zhao</last_name>
      <phone>13930162111</phone>
      <email>Zhaoqun516@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Qun Zhao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

